AAM
FATE icon

Advisors Asset Management’s Fate Therapeutics FATE Stock Holding History

Advisors Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,644
Closed -$55K – 1430
2023
Q1 		$55K Sell
9,644
-326
-3% -$1.97K ﹤0.01% 1296
2022
Q4 		$101K Sell
9,970
-22,843
-70% -$429K ﹤0.01% 1246
2022
Q3 		$735K Sell
32,813
-746
-2% -$21.6K 0.01% 830
2022
Q2 		$832K Sell
33,559
-6,183
-16% -$171K 0.01% 808
2022
Q1 		$1.54M Sell
39,742
-3,304
-8% -$128K 0.02% 670
2021
Q4 		$2.52M Buy
43,046
+1,678
+4% +$95.1K 0.04% 530
2021
Q3 		$2.45M Buy
41,368
+5,902
+17% +$463K 0.04% 533
2021
Q2 		$3.08M Buy
35,466
+5,796
+20% +$467K 0.04% 451
2021
Q1 		$2.45M Buy
29,670
+12,128
+69% +$1.16M 0.04% 517
2020
Q4 		$1.59M Buy
17,542
+11,109
+173% +$690K 0.02% 642
2020
Q3 		$257K Buy
6,433
+2,980
+86% +$104K ﹤0.01% 1106
2020
Q2 		$118K Buy
+3,453
New +$103K ﹤0.01% 1269

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Advisors Asset Management's FATE Position: Q2 2023 in Review

Advisors Asset Management sold out of Fate Therapeutics (FATE) in Q2 2023, closing a stake of 9,644 shares — an estimated $55K sold.

Advisors Asset Management first reported a position in FATE in Q2 2020 and held it in 12 quarters. The position peaked at $3.08M in Q2 2021. 188 funds tracked by Wall St. Rank hold FATE as of Q2 2023.

  • Advisors Asset Management reported no remaining Fate Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Advisors Asset Management sold 9,644 Fate Therapeutics shares in Q2 2023, an estimated $55K.
  • Advisors Asset Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 12 quarters.
  • Advisors Asset Management's Fate Therapeutics position peaked at $3.08M in Q2 2021.
  • 188 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2023.

Based on Advisors Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.